

1. **Yoshimatsu Y**, Noguchi R, Osaki J, Sin Y, Tsuchiya R, Ono T, Akiyama T, Adachi Y, Tanzawa Y, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-LMS3-C1: a novel patient-derived cell line of leiomyosarcoma. Hum Cell. Epub 2023 Oct 31.
2. Akiyama T, **Yoshimatsu Y**, Noguchi R, Sin Y, Osaki J, Ono T, Adachi Y, Tsuchiya R, Toda Y, Ogura K, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-DFSP4-C1: a novel cell line from a patient with dermatofibrosarcoma protuberans having the fibrosarcomatous transformation. Hum Cell. 2023 Nov;36(6):2187-2194.
3. Ono T, Noguchi R, **Yoshimatsu Y**, Sin Y, Tsuchiya R, Akiyama T, Kojima N, Toda Y, Sato C, Fukushima S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone. Hum Cell. 2023 Sep;36(5):1804-1812.
4. Tsuchiya R, **Yoshimatsu Y**, Noguchi R, Sin Y, Ono T, Akiyama T, Kosako H, Yoshida A, Ohtori S, Kawai A, Kondo T. Integrating analysis of proteome profile and drug screening identifies therapeutic potential of MET pathway for the treatment of malignant peripheral nerve sheath tumor. Expert Rev Proteomics. 2023 Apr-Jun;20(4-6):109-119.
5. Isoyama S, Tamaki N, Noguchi Y, Okamura M, **Yoshimatsu Y**, Kondo T, Suzuki T, Yaguchi SI, Dan S. Subtype-selective induction of apoptosis in translocation-related sarcoma cells induced by PUMA and BIM upon treatment with pan-PI3K inhibitors. Cell Death Dis. 2023 Feb 27;14(2):169.
6. Akiyama T, **Yoshimatsu Y**, Noguchi R, Sin Y, Osaki J, Ono T, Adachi Y, Tsuchiya R, Toda Y, Kobayashi E, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-DSM1-C1: a novel cell line derived from a patient with desmoid fibromatosis. Hum Cell. 2023 Mar;36(2):847-853.
7. Akiyama T, **Yoshimatsu Y**, Noguchi R, Sin Y, Osaki J, Adachi Y, Ono T, Tsuchiya R, Sato C, Iwata S, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-PLPS2-C1: a novel cell line of pleomorphic liposarcoma. Hum Cell. 2023 Jan;36(1):468-475.
8. **Yoshimatsu Y**, Noguchi R, Sin Y, Tsuchiya R, Ono T, Akiyama T, Sato C, Kobayashi E, Kojima N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-MFS6-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2022 Nov;35(6):1993-2001.
9. Akiyama T, **Yoshimatsu Y**, Noguchi R, Sin Y, Tsuchiya R, Ono T, Sugaya J, Kobayashi E, Yoshida A,

Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-PS1-C1: a novel cell line of pleomorphic sarcoma from a patient after neoadjuvant radiotherapy. *Hum Cell*. 2022 Nov;35(6):2011-2019.

10. Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Sato C, Kojima N, Yoshida A, Kawai A, Ohtori S, Kondo T. Establishment and characterization of NCC-MRT1-C1: a novel cell line of malignant rhabdoid tumor. *Hum Cell*. 2022 Nov;35(6):2002-2010.
11. Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Akiyama T, Nakagawa R, Kamio S, Hirabayashi K, Ozawa I, Kikuta K, Kondo T. Establishment and characterization of a novel patient-derived cell line of dedifferentiated liposarcoma, NCC-DDLPS6-C1. *Hum Cell*. 2022 Jul;35(4):1270-1278.
12. Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Akiyama T, Sugaya J, Kojima N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-SS5-C1: a novel patient-derived cell line of synovial sarcoma. *Hum Cell*. 2022 Jul;35(4):1290-1297.
13. Noguchi R, Yoshimatsu Y, Sin Y, Tsuchiya R, Ono T, Akiyama T, Hirabayashi K, Ozawa I, Nakagawa R, Kikuta K, Kondo T. Establishment and characterization of two novel patient-derived myxoid liposarcoma cell lines. *Hum Cell*. 2022 Jul;35(4):1279-1289.
14. Sin Y, Ono T, Tsuchiya R, Noguchi R, Yoshimatsu Y, Kosako H, Kondo T. Proteomic analysis of spheroids of rhabdomyosarcoma cells cultured with decellularized muscle extracts. *J Electrophoresis*. 2022; 66(1):1-4.
15. Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Akiyama T, Nakagawa R, Kamio S, Hirabayashi K, Ozawa I, Kikuta K, Kondo T. Establishment and characterization of a novel patient-derived Ewing sarcoma cell line, NCC-ES2-C1. *Hum Cell*. 2022 Jul;35(4):1262-1269.
16. Sin Y, Yoshimatsu Y, Noguchi R, Tsuchiya R, Ono T, Akiyama T, Iwata S, Sugaya J, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. *Hum Cell*. 2022 May;35(3):936-943.
17. Yuki Yoshimatsu, Rei Noguchi, Yooksil Sin, Ryuto Tsuchiya, Takuya Ono, Taro Akiyama, Rumi Nakagawa, Satoshi Kamio, Kaoru Hirabayashi, Iwao Ozawa, Kazutaka Kikuta, Tadashi Kondo: Establishment and characterization of a novel patient derived Ewing sarcoma cell line, NCC ES2 C1. *Human Cell*. 35(4), 1262-1269, 2022. DOI: 10.1007/s13577-021-00571-8.
18. Takuya Ono, Yuki Yoshimatsu, Rei Noguchi, Yooksil Sin, Ryuto Tsuchiya, Taro Akiyama, Jun Sugaya,

Suguru Fukushima, Naoki Kojima, Akihiko Yoshida, Akira Kawai, Tadashi Kondo: Establishment and characterization of NCC UPS4 C1: a novel cell line of undifferentiated pleomorphic sarcoma from a patient with Li Fraumeni syndrome. *Human Cell*. 35(2), 756-766, 2022. DOI: 10.1007/s13577-021-00549-6.

19. Rei Noguchi, **Yuki Yoshimatsu**, Yooksil Sin, Takuya Ono, Ryuto Tsuchiya, Hiroshi Yoshida, Tohru Kiyono, Yutaka Yonemura, Tadashi Kondo: Establishment and Characterization of NCC PMP1 C1: A Novel Patient Derived Cell Line of Metastatic Pseudomyxoma Peritonei. *Journal of Personalized Medicine*. 12(2), 258-258, 2022. DOI: 10.3390/jpm12020258.
20. Ryuto Tsuchiya, **Yuki Yoshimatsu**, Rei Noguchi, Yooksil Sin, Takuya Ono, Taro Akiyama, Jun Sugaya, Eisuke Kobayashi, Naoki Kojima, Akihiko Yoshida, Seiji Ohtori, Akira Kawai, Tadashi Kondo: Establishment and Characterization of NCC MFS5 C1: A Novel Patient Derived Cell Line of Myxofibrosarcoma. *Cells*. 11(2), 207-207, 2022. DOI: 10.3390/cells11020207.
21. Yooksil Sin, Takuya Ono, Ryuto Tsuchiya, Rei Noguchi, **Yuki Yoshimatsu**, Hidetaka Kosako, Tadashi Kondo: Proteomic analysis of spheroids of rhabdomyosarcoma cells cultured with decellularized muscle extracts. *Journal of Electrophoresis*. 66(1), 1-4, 2022. DOI: 10.1016/j.joe.2021.10.004.
22. Ryuto Tsuchiya, **Yuki Yoshimatsu**, Rei Noguchi, Yooksil Sin, Takuya Ono, Taro Akiyama, Jun Sugaya, Fumihiko Nakatani, Naoki Kojima, Akihiko Yoshida, Seiji Ohtori, Akira Kawai, Tadashi Kondo: Establishment and characterization of NCC UPS3 C1: a novel patient derived cell line of undifferentiated pleomorphic sarcoma. *Human Cell*. 35(1), 384-391, 2022. DOI: 10.1007/s13577-021-00523-2.
23. Rei Noguchi, **Yuki Yoshimatsu**, Takuya Ono, Akane Sei, Noriko Motoi, Yasushi Yatabe, Yukihiro Yoshida, Shunichi Watanabe, Tadashi Kondo: Establishment and characterization of NCC-DMM1-C1, a novel patient-derived cell line of desmoplastic malignant pleural mesothelioma. *Oncology Letters*. 23(2), 2021. DOI: 10.3892/ol.2021.12517.
24. Yooksil Sin, **Yuki Yoshimatsu**, Rei Noguchi, Ryuto Tsuchiya, Takuya Ono, Taro Akiyama, Fumihiko Nakatani, Jun Sugaya, Akihiko Yoshida, Akira Kawai, Tadashi Kondo: Establishment and characterization of NCC-MPNST6-C1: a novel patient-derived cell line of malignant peripheral nerve sheath tumors. *Human Cell*. 35(1), 400-407, 2021. DOI: 10.1007/s13577-021-00502-7.
25. Takuya Ono, Rei Noguchi, **Yuki Yoshimatsu**, Ryuto Tsuchiya, Yooksil Sin, Rumi Nakagawa, Kaoru Hirabayashi, Iwao Ozawa, Kazutaka Kikuta, Tadashi Kondo: Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone. *Human Cell*.

34(6), 1899-1910, 2021. DOI: 10.1007/s13577-021-00595-y.

26. **Yuki Yoshimatsu**, Rei Noguchi, Ryuto Tsuchiya, Takuya Ono, Yooksil Sin, Akane Sei, Jun Sugaya, Tomoaki Mori, Suguru Fukushima, Akihiko Yoshida, Akira Kawai, Tadashi Kondo: Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone. *Human Cell*. 34(6), 1899-1910, 2021. DOI: 10.1007/s13577-021-00594-1.
27. **Yuki Yoshimatsu**, Rei Noguchi, Ryuto Tsuchiya, Yooksil Sin, Takuya Ono, Jun Sugaya, Shintaro Iwata, Akihiko Yoshida, Akira Kawai, Tadashi Kondo: Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma. *Human Cell*. 34(6), 1911-1918, 2021. DOI: 10.1007/s13577-021-00593-2.
28. **Yuki Yoshimatsu**, Rei Noguchi, Yooksil Sin, Ryuto Tsuchiya, Takuya Ono, Akane Sei, Jun Sugaya, Shintaro Iwata, Akihiko Yoshida, Akira Kawai, Tadashi Kondo: Establishment and characterization of NCC-LGFMS1-C1: a novel patient-derived cell line of low-grade fibromyxoid sarcoma. *Human Cell*. 34(6), 1919-1928, 2021. DOI: 10.1007/s13577-021-00592-3.
29. Ryuto Tsuchiya, **Yuki Yoshimatsu**, Rei Noguchi, Yooksil Sin, Takuya Ono, Taro Akiyama, Takeshi Hirose, Shintaro Iwata, Akihiko Yoshida, Seiji Ohtori, Akira Kawai, Tadashi Kondo: Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma. *Journal of Personalized Medicine*. 11(11), 1075-1075, 2021. DOI: 10.3390/jpm11111075.
30. Aoi Komatsu, Kotaro Matsumoto, **Yuki Yoshimatsu**, Yooksil Sin, Arisa Kubota, Tomoki Saito, Ayaka Mizumoto, Shinya Ohashi, Manabu Muto, Rei Noguchi, Tadashi Kondo, Fuyuhiko Tamanoi: The CAM Model for CIC-DUX4 Sarcoma and Its Potential Use for Precision Medicine. *Cells*. 10(10), 2613-2613, 2021. DOI: 10.3390/cells10102613.
31. Ryuto Tsuchiya, **Yuki Yoshimatsu**, Rei Noguchi, Yooksil Sin, Takuya Ono, Akane Sei, Fumitaka Takeshita, Jun Sugaya, Fumihiko Nakatani, Akihiko Yoshida, Seiji Ohtori, Akira Kawai, Tadashi Kondo: Establishment and characterization of NCC-ssRMS2-C1: a novel patient-derived cell line of spindle cell/sclerosing rhabdomyosarcoma. *Human Cell*. 34(5), 1569-1578, 2021. DOI: 10.1007/s13577-021-00511-6.
32. Takuya Ono, Rei Noguchi, **Yuki Yoshimatsu**, Yooksil Sin, Nobuhiko Kojima, Tadashi Kondo: Development of different organ derived decellularized tissue gels that support in vitro tumor cell behavior in a tumor type-specific manner. *Journal of Electrophoresis*. 65(1), 33-37, 2021. DOI: 10.1016/j.elecrep.2020.11.006.

33. Takuya Ono, Rei Noguchi, Yuki Yoshimatsu, Yooksil Sin, Nobuhiko Kojima, Tadashi Kondo: Development of an in vitro culture system using decellularized tissue gels. Electrophoresis Letters, 65(2), 75-78 (2021).
34. Ryuto Tsuchiya, Yuki Yoshimatsu, Rei Noguchi, Akane Sei, Fumitaka Takeshita, Jun Sugaya, Suguru Fukushima, Akihiko Yoshida, Seiji Ohtori, Akira Kawai, Tadashi Kondo: Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. Human Cell, 34(1), 260-270 (2021).
35. Rei Noguchi, Yuki Yoshimatsu, Takuya Ono, Akane Sei, Kaoru Hirabayashi, Iwao Ozawa, Kazutaka Kikuta, Tadashi Kondo: Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor. Human Cell, 34(1), 254-259 (2021).
36. Rei Noguchi, Yuki Yoshimatsu, Takuya Ono, Akane Sei, Kaoru Hirabayashi, Iwao Ozawa, Kazutaka Kikuta, Tadashi Kondo: Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma. Human Cell, 34(1), 246-253 (2021).
37. Rei Noguchi, Yuki Yoshimatsu, Akane Sei, Hiroshi Yoshida, Tomoyasu Katou, Tadashi Kondo: Drug screening and kinase activity profiling of a novel patient-derived cell line of clear cell ovarian carcinoma. Journal of Electrophoresis, 65(1), 23-31 (2021).
38. Rei Noguchi, Yuki Yoshimatsu, Takuya Ono, Akane Sei, Tadashi Kondo: Proteogenomic approach to drug targets in osteosarcomas with different original sites. Journal of Electrophoresis, 65(1), 1-11 (2021).
39. 申育實, 野口玲, 吉松有紀, 土屋流人, 小野拓也, 清茜, 川井章, 近藤格 : 患者由来がん細胞株を用いた未分化多形肉腫のキナーゼ活性およびキナーゼ阻害剤の統合解析. 電気泳動, 64(Suppl.), s37 (2020 年 11 月).
40. 吉松有紀, 野口玲, 申育實, 土屋流人, 小野拓也, 清茜, 菊田一貴, 川井章, 近藤格 : 患者由来「肉腫」モデルの樹立機能的なオミクスデータの解釈に向けて. 電気泳動, 64(Suppl.), s40 (2020 年 11 月).
41. 土屋流人, 吉松有紀, 野口玲, 申育實, 小野拓也, 清茜, 近藤格 : 肉腫の組織型に特徴的な発現パターンを示す miRNA の同定. 電気泳動, 64(Suppl.), s42 (2020 年 11 月).
42. 小野拓也, 野口玲, 吉松有紀, 申育實, 清茜, 土屋流人, 近藤格 : 脱細胞化ゲルによる新規培養系の確立. 電気泳動, 64(Suppl.), s50 (2020 年 11 月).

43. 野口玲, 吉松有紀, 申育實, 小野拓也, 土屋流人, 清茜, 英尊 小迫, 近藤格 : OncoProGx 電気泳動法の未来を切り拓く革新的なソフトウェア. 電気泳動, 64(Suppl.), s51 (2020 年 11 月).
44. 吉松有紀, 野口玲, 土屋流人, 申育實, 真美 高橋, 川井章, 近藤格 : 国立がん研究センターにおける患者由来がん肉腫モデル. 日本癌学会総会記事, 79 回 PJ2-8 (2020 年 10 月).
45. 野口玲, 吉松有紀, 星暢夫, 菊田一貴, 近藤格 : 患者由来モデルを用いた粘液型脂肪肉腫の新しい治療の探索薬剤スクリーニングとキナーゼ活性プロファイリングを用いて. 日本癌学会総会記事, 79 回 OJ2-2 (2020 年 10 月).
46. 申育實, 吉松有紀, 野口玲, 土屋流人, 高橋真美, 小林英介, 吉田朗彦, 川井章, 近藤格 : PAX7-FOXO1 融合遺伝子をもつ新規胞巣型横紋筋肉腫細胞株 NCC-aRMS1-C1 の樹立と特性解析. 日本癌学会総会記事, 79 回 PJ11-110 (2020 年 10 月).
47. Yuki Yoshimatsu, Rei Noguchi, Ryuto Tsuchiya, Akane Sei, Jun Sugaya, Suguru Fukushima, Akihiko Yoshida, Akira Kawai, Tadashi Kondo: Establishment and characterization of NCC-ASPS1-C1: a novel patient-derived cell line of alveolar soft-part sarcoma. Human Cell, 33(4), 1302-1310 (2020 年 10 月).
48. Yooksil Sin, Yuki Yoshimatsu, Rei Noguchi, Ryuto Tsuchiya, Akane Sei, Takuya Ono, Shunichi Toki, Eisuke Kobayashi, Ayumu Arakawa, Masanaka Sugiyama, Akihiko Yoshida, Akira Kawai, Tadashi Kondo: Establishment and characterization of a novel alveolar rhabdomyosarcoma cell line, NCC-aRMS1-C1. Human Cell, 33(4), 1311-1320 (2020 年 10 月).
49. Rei Noguchi, Yuki Yoshimatsu, Takuya Ono, Akane Sei, Kaoru Hirabayashi, Iwao Ozawa, Kazutaka Kikuta, Tadashi Kondo: Establishment and characterization of NCC-GCTB1-C1: a novel patient-derived cancer cell line of giant cell tumor of bone. Human Cell, 33(4), 1321-1328 (2020 年 10 月).
50. Yuki Yoshimatsu, Rei Noguchi, Ryuto Tsuchiya, Akane Sei, Jun Sugaya, Shintaro Iwata, Masanaka Sugiyama, Akihiko Yoshida, Akira Kawai, Tadashi Kondo: Establishment and characterization of NCC-ssRMS1-C1: a novel patient-derived spindle-cell/sclerosing rhabdomyosarcoma cell line. Human Cell, 33(3), 886-893 (2020 年 7 月).
51. 土屋流人, 野口玲, 吉松有紀, 申育實, 清茜, 岩田慎太郎, 川井章, 近藤格 : 患者由来がんモデルの構築. 日本整形外科学会雑誌, 94(6) S1410 (2020 年 7 月).
52. 土屋流人, 野口玲, 吉松有紀, 申育實, 清茜, 岩田慎太郎, 川井章, 近藤格 : International Cancer Proteogenomics Consortium(ICPC)の活動の紹介. 日本整形外科学会雑誌, 94(6) S1410 (2020 年 7

月).

53. 土屋流人, 野口玲, 吉松有紀, 申育實, 清茜, 岩田慎太郎, 川井章, 近藤格 : miRNA アレイにより同定した肉腫組織型ごとの miRNA 発現の特徴. 日本整形外科学会雑誌, 94(6) S1570 (2020 年 7 月).
54. Yuki Yoshimatsu, Rei Noguchi, Ryuto Tsuchiya, Akane Sei, Jun Sugaya, Shintaro Iwata, Akihiko Yoshida, Akira Kawai, Tadashi Kondo: Establishment and characterization of NCC-SS3-C1: a novel patient-derived cell line of synovial sarcoma. Human Cell 33(3): 877-885, 2020. doi: 10.1007/s13577-020-00353-7.
55. Yuki Yoshimatsu, Rei Noguchi, Ryuto Tsuchiya, Akane Sei, Makoto Nakagawa, Akihiko Yoshida, Akira Kawai, Tadashi Kondo: Establishment and characterization of NCC-DFSP3-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line. Human Cell 33(3): 894-903, 2020. doi: 10.1007/s13577-020-00355-5.
56. Yuki Yoshimatsu, Rei Noguchi, Ryuto Tsuchiya, Fusako Kito, Akane Sei, Jun Sugaya, Makoto Nakagawa, Akihiko Yoshida, Shintaro Iwata, Akira Kawai, Tadashi Kondo: Establishment and characterization of NCC-CDS2-C1: a novel patient-derived cell line of CIC-DUX4 sarcoma. Human Cell 33(2): 427-436, 2020. doi: 10.1007/s13577-020-00310-4.
57. Rei Noguchi, Rieko Koyama, Yuki Yoshimatsu, Emi Hattori, Akira Kawai, Tadashi Kondo: Osteosarcomas with different original sites exhibit distinct response to anti-cancer drugs due to biological properties. 日本癌学会総会記事 78: 2331, 2019.
58. Ghani, Dendo, Watanabe, Yamada, Yoshimatsu, Yugawa, Nakahara, Tanaka, Yoshida, Ishikawa, Goshima, Kato, Kiyono: An Ex-Vivo Culture System of Ovarian Cancer Faithfully Recapitulating the Pathological Features of Primary Tumors. Cells 8(7): 644, 2019. doi: 10.3390/cells8070644.
59. Juri Ogishima, Ayumi Taguchi, Akira Kawata, Kei Kawana, Mitsuyo Yoshida, Yuki Yoshimatsu, Masakazu Sato, Hiroe Nakamura, Yoshiko Kawata, Akira Nishijima, Asaha Fujimoto, Kensuke Tomio, Katsuyuki Adachi, Takeshi Nagamatsu, Katsutoshi Oda, Tohru Kiyono, Yutaka Osuga, Tomoyuki Fujii: The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway. BMC Cancer 18(1), 2018. doi: 10.1186/s12885-018-4254-6.
60. Yuki Yoshimatsu, Tomomi Nakahara, Katsuyuki Tanaka, Yuki Inagawa, Mako Narisawa-Saito, Takashi Yugawa, Shin-ichi Ohno, Masatoshi Fujita, Hitoshi Nakagama, Tohru Kiyono: Roles of the PDZ-binding motif of HPV 16 E6 protein in oncogenic transformation of human cervical keratinocytes. Cancer Science 108(7): 1303-1309, 2017. doi: 10.1111/cas.13257.

61. Mako Narisawa-Saito, Yuki Inagawa, Yuki Yoshimatsu, Kei Haga, Katsuyuki Tanaka, Nagayasu Egawa, Shin-ichi Ohno, Hitoshi Ichikawa, Takashi Yugawa, Masatoshi Fujita, Tohru Kiyono: A critical role of MYC for transformation of human cells by HPV16 E6E7 and oncogenic HRAS. *Carcinogenesis* 33(4): 910-917, 2012. doi: 10.1093/carcin/bgs024.
62. Tatsuhiko Shibata, Akiko Kokubu, Shigeru Saito, Mako Narisawa-Saito, Hiroki Sasaki, Kazuhiko Aoyagi, Yuki Yoshimatsu, Yuji Tachimori, Ryoji Kushima, Tohru Kiyono, Masayuki Yamamoto: NRF2 Mutation Confers Malignant Potential and Resistance to Chemoradiation Therapy in Advanced Esophageal Squamous Cancer. *Neoplasia* 13(9): 864-IN26, 2011. doi: 10.1593/neo.11679.
63. Yusuke Zushi, Mako Narisawa-Saito, Kaoru Noguchi, Yuki Yoshimatsu, Takashi Yugawa, Nagayasu Egawa, Masatoshi Fujita, Makoto Urade, Tohru Kiyono: An in vitro multistep carcinogenesis model for both HPV-positive and HPV-negative human oral squamous cell carcinomas. *Am J Cancer Res.* 1(7): 869-81, 2011. Epub 2011 Aug 18. PMID: 22016834; PMCID: PMC3196285.
64. Takashi Yugawa, Mako Narisawa-Saito, Yuki Yoshimatsu, Kei Haga, Shin-ichi Ohno, Nagayasu Egawa, Masatoshi Fujita, Tohru Kiyono: Δ Np63 α Repression of the Notch1 Gene Supports the Proliferative Capacity of Normal Human Keratinocytes and Cervical Cancer Cells. *Cancer Research* 70(10): 4034-4044, 2010. doi: 10.1158/0008-5472.CAN-09-3954.
65. Mako Narisawa-Saito, Yuki Yoshimatsu*, Shin-ichi Ohno, Takashi Yugawa, Nagayasu Egawa, Masatoshi Fujita, Setsuo Hirohashi, Tohru Kiyono: An In vitro Multistep Carcinogenesis Model for Human Cervical Cancer. *Cancer Research* 68(14): 5699-5705, 2008. doi: 10.1158/0008-5472.CAN-07-6331.

学会・研究会発表

1. Yoshimatsu Y, Sugihara Y, Mari K, Noguchi R, Kondo T. Patient-derived cancer models and pharmaco-proteogenomics toward novel therapy. European Society of Medicine General Assembly 2022 (2022/8/4) 招待講演
2. 吉松有紀: 平滑筋肉腫の細胞株の樹立とその性状の解析および薬効評価スクリーニング. 第 41 回日本ヒト細胞学会学術集会 (2023/8/27)
3. 近藤 格、野口 玲、吉松有紀: がんゲノム医療の時代の患者由来肉腫モデル. 第 6 回日本サルコーマ治療研究学会学術集会 (2023/2/24-25)
4. Adachi Y, Noguchi R, Ono T, Osaki J, Yanagihara K, Sasaki K, Yoshimatsu Y, Yokoo H, Ohtsuki S, Kondo T: Comprehensive Proteomic Analysis of FFPE Specimens in Hepatocellular Carcinoma for Investigating Recurrence Mechanism. 22nd Human Proteome Organization World Congress (2023/9/19)
5. Yuki Yoshimatsu, Yutaka Sugihara, Keigo Amari, Rei Noguchi, Tadashi Kondo: Patient-derived cancer models and pharmaco-proteogenomics toward novel therapy. 第 81 回日本癌学会学術総会 (2022/9/30) シンポジウム講演

書籍執筆

1. 吉松有紀、野口玲、近藤格. 「骨軟部肉腫」分子腫瘍マーカー 診療ガイドライン 第2版 189－195 ページ、日本分子腫瘍マーカー研究会編 金原出版株式会社
2. 吉松有紀、近藤格. 「患者由来「希少がんの未来を変える患者由来がんモデル」「希少がんーがん診療の新たな課題ー」日本臨牀 79 巻増刊号 1 (2021 年 3 月 31 日発行)

研究費

がんモデルとプロテオゲノミクスを用いた隆起性皮膚線維肉腫の新規治療法の開発

日本学術振興会: 科学研究費助成事業 基盤研究(C)

2022 年 4 月 1 日 - 2025 年 3 月 31 日 吉松 有紀, 近藤 格, 川井 章

肉腫におけるトラベクテジンの奏効性と融合遺伝子の相関の分子背景を調べる研究

日本学術振興会: 科学研究費助成事業 基盤研究(C)

2022 年 4 月 1 日 - 2025 年 3 月 31 日 近藤 格, 小迫 英尊, 野口 玲, 吉松 有紀, 川井 章

プロテオゲノミクスを用いた悪性骨軟部腫瘍の新たな診断・治療標的の探索

日本学術振興会: 科学研究費助成事業 基盤研究(B)

2021 年 4 月 1 日 - 2024 年 3 月 31 日 川井 章, 近藤 格, 市川 仁, 吉田 朗彦, 平田 真, 野口 玲, 吉松 有紀

がんゲノム医療の限界を克服する患者由来「希少がん」モデルを用いた研究

国立研究開発法人日本医療研究開発機構（AMED）：若手（領域1）がんの本態解明に関する研究（領域1-1）がんの最適医療の実現に資する基盤的研究と臨床的有用性の検証

2020年4月 - 2022年3月 吉松 有紀

PD-L1 安定化因子 CMTM6 による Ewing 肉腫転移誘発機構の解明

日本学術振興会：科学研究費助成事業 若手研究

2018年4月1日 - 2022年3月31日 吉松 有紀

プロテオゲノミクスによる悪性骨軟部腫瘍の新たなバイオマーカーの探索とその応用

日本学術振興会：科学研究費助成事業 基盤研究(B)

2018年4月1日 - 2021年3月31日 川井 章, 近藤 格, 市川 仁, 吉田 朗彦, 野口 玲, 吉松 有紀, 小山 理恵子, 服部 恵美

miRNA-エクソソーム輸送複合体の同定とがん病態誘発との関連

日本学術振興会：科学研究費助成事業 挑戦的萌芽研究

2014年4月1日 - 2017年3月31日 土屋 直人, 吉松 有紀

受賞

2023年 優秀演題賞 平滑筋肉腫の細胞株の樹立とその性状の解析および薬効評価スクリーニング
日本ヒト細胞学会学術集会 吉松 有紀

2021年 ポスター賞 「患者由来「肉腫」モデルの構築」 患者由来がんモデル研究会 吉松 有紀

2010年 海外留学助成 子宮頸がん多段階発がん機構の解析 神澤医学研究振興財団 吉松 有紀

教育・社会活動

（教育）

2021年 武蔵野大学 薬学部 講義 「培養細胞を用いたがん研究」 吉松 有紀

2021年 長崎大学大学院 医歯薬学総合研究科 講義 「肉腫の患者由来がんモデル至適培地の工夫と希少がん研究の展望」 吉松 有紀

（社会活動）

2020年 肉腫の患者会（たんぽぽの会）の方にご協力いただき、「患者由来がんモデル講演会」の企画・運営に参加した。自分のがん研究をわかりやすく患者さんに伝えると同時に、患者会の方ご自身の闘病生活の体験についてウェブ講演で全国に語っていただいた。